Notably, recent evidence suggests that HER2-low breast cancers (defined as IHC 1+ or FISH-negative IHC 2+) may benefit from trastuzumab deruxtecan [30], underscoring the clinical importance of accurate HER2-low identification. Here, ERBB2 is linked to breast cancer.